CA2156525A1 - Compositions a base de lipide a monophosphoryle 3-o-desacyle pour des vaccins anti-grippe - Google Patents

Compositions a base de lipide a monophosphoryle 3-o-desacyle pour des vaccins anti-grippe

Info

Publication number
CA2156525A1
CA2156525A1 CA002156525A CA2156525A CA2156525A1 CA 2156525 A1 CA2156525 A1 CA 2156525A1 CA 002156525 A CA002156525 A CA 002156525A CA 2156525 A CA2156525 A CA 2156525A CA 2156525 A1 CA2156525 A1 CA 2156525A1
Authority
CA
Canada
Prior art keywords
mpl
vaccine composition
composition according
protein
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002156525A
Other languages
English (en)
Inventor
Susan Dillon
Hirotoshi Nishikawa
Paul Dal Monte
Robert J. Gyurik
Nathalie Marie-Josephe Claude Garcon-Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2156525A1 publication Critical patent/CA2156525A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
CA002156525A 1993-02-19 1994-02-15 Compositions a base de lipide a monophosphoryle 3-o-desacyle pour des vaccins anti-grippe Abandoned CA2156525A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2153593A 1993-02-19 1993-02-19
US08/021,535 1993-02-19
US11575093A 1993-09-01 1993-09-01
US08/115,750 1993-09-01

Publications (1)

Publication Number Publication Date
CA2156525A1 true CA2156525A1 (fr) 1994-09-01

Family

ID=26694802

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002156525A Abandoned CA2156525A1 (fr) 1993-02-19 1994-02-15 Compositions a base de lipide a monophosphoryle 3-o-desacyle pour des vaccins anti-grippe

Country Status (9)

Country Link
EP (1) EP0684838A1 (fr)
AP (1) AP431A (fr)
AU (1) AU6141094A (fr)
CA (1) CA2156525A1 (fr)
IL (1) IL108681A0 (fr)
MA (1) MA23118A1 (fr)
MX (1) MX9401225A (fr)
SI (1) SI9400085A (fr)
WO (1) WO1994019013A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
DK0812593T4 (da) * 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6261573B1 (en) * 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
WO2002067983A1 (fr) * 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Nouveau vaccin
WO2002074336A2 (fr) * 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Vaccin
CA2445120A1 (fr) * 2001-04-27 2002-11-07 Glaxosmithkline Biologicals Sa Nouveau vaccin
ES2386272T3 (es) 2004-09-09 2012-08-16 Novartis Vaccines And Diagnostics Gmbh Reducción de riesgos iatrogénicos potenciales asociados a las vacunas antigripales
AU2005314563B2 (en) 2004-11-03 2011-06-30 Seqirus UK Limited Influenza vaccination
PT1861120T (pt) 2005-03-23 2016-08-18 Glaxosmithkline Biologicals Sa Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
BRPI0721393B8 (pt) * 2007-03-22 2022-09-06 Fund Butantan método para obter lipídeo a monofosforilado da bordetella pertussis como um subproduto da produção de vacina celular contra coqueluche
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
EA201071086A1 (ru) * 2008-03-18 2011-04-29 Новартис Аг Усовершенствованный способ получения вакцинных антигенов вируса гриппа
EP3012330A1 (fr) 2010-09-07 2016-04-27 Novartis AG Dosages génériques de détection de réovirus de mammifère
SG10201808312YA (en) * 2014-03-25 2018-10-30 The Government Of The Us Secretary Of The Army Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
AU2019302562A1 (en) * 2018-07-10 2021-01-14 Seqirus Pty Ltd Removal of agglomerates
CN112361796A (zh) * 2020-11-13 2021-02-12 安徽省天长市周氏羊业有限公司 一种秸秆回收储存前破碎干燥装置
CN114989269B (zh) * 2022-06-30 2023-09-19 天康制药股份有限公司 一种牛赤羽免疫原性抗原及疫苗

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
US5230899A (en) * 1985-08-07 1993-07-27 Smithkline Beecham Corporation Methods and compositions for making liposomes
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
AU631377B2 (en) * 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
AU640348B2 (en) * 1988-08-31 1993-08-26 Smithkline Beecham Corporation Vaccinal Polypeptides
DK425789A (da) * 1988-08-31 1990-03-01 Smithkline Beecham Corp Vaccinale polypeptider
EP0644201A1 (fr) * 1990-09-28 1995-03-22 SMITHKLINE BEECHAM BIOLOGICALS s.a. Dérivés de gp160 et vaccines à base de gp160 ou d'un de ses dérivés, contenant un adjuvant
WO1992011291A1 (fr) * 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) VACCINS A BASE DE l'ANTIGENE D'ENVELOPPE DU VIRUS DE L'HEPATITE B
FR2671974A1 (fr) * 1991-01-24 1992-07-31 Pasteur Merieux Serums Vacc Composition vaccinale contre la grippe, a effet synergique, contenant comme additif du core de virus grippal.
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
KR100278157B1 (ko) * 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물

Also Published As

Publication number Publication date
AP431A (en) 1995-11-15
EP0684838A1 (fr) 1995-12-06
AU6141094A (en) 1994-09-14
WO1994019013A1 (fr) 1994-09-01
AP9400621A0 (en) 1994-04-30
MA23118A1 (fr) 1994-10-01
SI9400085A (en) 1994-09-30
IL108681A0 (en) 1994-05-30
MX9401225A (es) 1994-08-31

Similar Documents

Publication Publication Date Title
AP431A (en) Influenza vaccine compositions.
KR101916787B1 (ko) Ｃｄ4 ｔ－세포 및/또는 개선된 ｂ－메모리 세포 반응을 유도하는 인플루엔자 바이러스 및 수중유 에멀젼 애주번트의 용도
US7604803B2 (en) Method to enhance an immune response of nucleic acid vaccination
ES2678694T3 (es) Vacuna
JP6119030B2 (ja) インフルエンザを治療するための組成物及び方法
JP2011506264A (ja) インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
CA2169297C (fr) Vaccins a base de cochleate proteique ou peptidique et procedes d'immunisation faisant appel a ces vaccins
EP2058002A1 (fr) Membranes reconstituées du virus respiratoire syncytial et utilisation en tant que vaccin contre le virus respiratoire syncytial
JP2011525190A (ja) インフルエンザを処置するための組成物および方法
JPH08506592A (ja) ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物
WO2012006368A2 (fr) Compositions et méthodes pour traiter la grippe
US20050152919A1 (en) Measles subunit vaccine
AU2007228736B2 (en) Intranasal influenza vaccine based on virosomes
MX2013003451A (es) Generacion de particulas de virosoma.
US10806779B2 (en) Method for preparing virosomes
Fujii et al. The VesiVax system: a method for rapid vaccine development
WO2020067302A1 (fr) Adjuvant muqueux
TWI771546B (zh) 針對亨德拉(hendra)及尼帕(nipah)病毒感染之疫苗
US20160151479A1 (en) Method for preparing virosomes
MX2008012046A (es) Vacuna intranasal contra la influenza, basada en virosomas.
JP2014015486A (ja) インフルエンザウイルスの４つの株に由来する抗原を含むワクチン

Legal Events

Date Code Title Description
FZDE Discontinued